SCHEMBL4124507

SCHEMBL4124507

CC(C)(C)OC(=O)NCCCC1=CC(=O)c2ccccc2C1=O

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MALT1 Q9UDY8 1/20 0.60
IDO1 P14902 3/20 0.46
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 1/20 0.44
TPSAB1 Q15661 1/20 0.43
TPSD1 Q9BZJ3 1/20 0.43
TPSG1 Q9NRR2 1/20 0.43
CA1 P00915 5/20 0.43
CA2 P00918 5/20 0.43
CA12 O43570 4/20 0.43
CA9 Q16790 4/20 0.43
CYP19A1 P11511 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
BRD4 O60885 1/20 0.42
SIGMAR1 Q99720 1/20 0.41
KCNA5 P22460 1/20 0.41
DRD2 P14416 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4105352 0.93 MALT1 (0.62) MALT1IDO1MEN1KMT2ACA1
SCHEMBL13649364 0.85 MALT1 (0.58) MALT1IDO1MEN1KMT2ACA1
SCHEMBL13649376 0.81 MALT1 (0.57) MALT1IDO1MEN1GAAKMT2A
SCHEMBL25754017 0.80 PTPRC (0.48) MALT1IDO1MEN1KMT2ACA1
SCHEMBL13814546 0.79 MALT1 (0.55) MALT1IDO1MEN1GAAKMT2A
SCHEMBL4034335 0.78 MALT1 (0.62) MALT1IDO1MEN1GAAKMT2A
SCHEMBL4583683 0.74 POLB (0.65) IDO1MEN1GAAKMT2ATDP1
SCHEMBL4124511 0.74 MEN1 (0.41) MALT1IDO1MEN1GAAKMT2A
SCHEMBL13649372 0.73 MALT1 (0.57) MALT1IDO1CA1CA2CA12
SCHEMBL4122496 0.73 MALT1 (0.57) MALT1IDO1CA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247472-A1 TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS FLUOFARMA (FR) 2009-10-01 US disclosed
US-20090247472-A1 TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS FLUOFARMA (FR) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247472-A1 TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS CCNA1, MKI67, CCNT1 MALT1 1105/4885IDO1 1244/4885MEN1 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.